Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;8(s1):S65-S72.
doi: 10.3233/JPD-181476.

Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson's Disease

Daniel J van Wamelen  1   2   3 , Sotirios Grigoriou  4 , K Ray Chaudhuri  1   2 , Per Odin  4   5
Affiliations
Review

Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson's Disease

Daniel J van Wamelen et al. J Parkinsons Dis. 2018.

Abstract

Continuous dopaminergic stimulation in Parkinson's disease (PD) has several advantages over pulsatile, non-continuous, stimulation. These therapies currently consist of pump-based and transcutaneous therapies and are based on a more constant delivery of the dopaminergic drug resulting in continuous dopaminergic stimulation and a more stable treatment effect. Several clinical and experimental observations have shown that continuous stimulation of dopaminergic receptors induces fewer complications, such as dyskinesia, compared to pulsatile stimulation. Currently available non-oral pharmacological continuous therapies in PD include the transdermal Rotigotine (RTG) patch, infusion therapies with Apomorphine and Intrajejunal Levodopa (IJLI) and the Rivastigmine patch. Here we aim to provide a concise review of these current therapies and discuss ongoing and future developments of continuous non-oral pharmacological dopaminergic therapies in PD.

Keywords: Parkinson’s disease; apomorphine; infusion pumps; rivastigmine; rotigotine.

PubMed Disclaimer

Figures

Fig.1
Fig.1
Overview of continuous dopaminergic therapy in Parkinson’s disease.
See this image and copyright information in PMC

References

    1. Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson’s disease: Scientific rationale and clinical implications. Lancet Neurol 5, 677–687. - PubMed
    1. Bibbiani F, Costantini LC, Patel R, Chase TN (2005) Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 192, 73–78. - PubMed
    1. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 342, 1484–1491. - PubMed
    1. Nutt JG, Obeso JA, Stocchi F (2000) Continuous dopamine receptor stimulation in advanced Parkinson’s disease. Trends Neurosci 23, 109–115. - PubMed
    1. Titova N, Schapira AHV, Chaudhuri KR, Katunina E, Jenner P (2017) Nonmotor symptoms in experimental models of Parkinson’s disease. Int Rev Neurobiol 133, 63–89. - PubMed

Publication types

MeSH terms